Title : KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.

Pub. Date : 2014 May

PMID : 24772300






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The median progression-free survival (mPFS) of the wild-type and mutated KRAS subgroups that had received oxaliplatin-based treatment was 8.6 and 6.8 months, respectively (P=0.41), whereas the mPFS of the wild-type KRAS, BRAF, PIK3CA, NRAS and AKT1 subgroups and that of their respective mutant subgroups was 9.7 and 7.2 months, respectively (P=0.10). Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens